On the occasion of World Cancer Research Day, held every September 24, the Vall d’Hebron Institute of Oncology (VHIO) reaffirms its commitment to advancing research in order to improve the survival and quality of life of cancer patients.
Throughout 2024, VHIO research teams have promoted collaborative science and clinical research in oncology through a multidisciplinary and translational model that directly connects the laboratory with clinical practice. This has been accompanied by the strengthening of scientific infrastructure and the launch of new initiatives and strategic alliances, both nationally and internationally, always keeping patients at the center.
The results of 2024 highlight the dynamism and excellence of the research conducted at VHIO:
- More than 800 professionals, organized into 36 research groups, 6 transversal units and 11 multidisciplinary task forces, along with 5 active spin-offs driving knowledge and technology transfer.
- 527 scientific articles published in international journals, with a median impact factor of 16.45, underscoring the relevance of the institute’s scientific output.
- Nearly 1,600 patients participated in 942 clinical trials active at some point during the year. Of these, 50% were early-phase studies carried out at the Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, consolidated as an international benchmark in phase I trials.
On this awareness day, VHIO emphasizes that research is the most effective way to transform the fight against cancer into hope for patients, and reaffirms its commitment to innovation, collaboration, and scientific excellence as drivers of change in oncology.
